| 董宇青,张瑞芳.MiR-26b增强顺铂对宫颈癌细胞株Hela的杀伤活性[J].浙江中西医结合杂志,2015,25(8): |
| MiR-26b增强顺铂对宫颈癌细胞株Hela的杀伤活性 |
| MiR-26b enhances the cytotoxicity of cisplatin by targeting in Mcl-1 in cervical cancer cell line Hela |
| 投稿时间：2015-03-26 修订日期：2015-06-10 |
| DOI： |
| 中文关键词: miR-26b Mcl-1 宫颈癌 Hela 顺铂 |
| 英文关键词:miR-26b Mcl-1 cervical cancer Hela cisplatin |
| 基金项目: |
|
| 摘要点击次数: 1135 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:研究microRNA-26b(miR-26b)是否能增强顺铂对宫颈癌细胞的杀伤活性及机制。方法:用荧光定量PCR方法检测人正常宫颈上皮细胞系CRL-2614及宫颈癌细胞系Hela、SiHa和C-33a miR-26b的表达水平。MTT法检测顺铂单独治疗及联合miR-26b治疗对宫颈癌细胞系Hela的杀伤活性。利用生物信息学及western blot方法验证miR-26b是否调节Hela细胞Mcl-1的表达。构建Mcl-1真核表达载体,MTT法检测Mcl-1表达载体转染对miR-26b联合顺铂杀伤Hela细胞疗效的影响。结果:宫颈癌细胞系Hela(0.21±0.04)、SiHa(0.42±0.03)和C-33a(0.33±0.03)的miR-26b的相对表达水平显著低于正常宫颈上皮细胞系CRL-2614 (1.00±0.05)。miR-26b联合1mmol/L顺铂治疗组对Hela细胞的杀伤活性(细胞活力抑制率为52.6±6.9)显著高于1mmol/L顺铂单治疗组(细胞活力抑制率为6.7±3.5)。miR-26b转染后,Hela细胞Mcl-1的蛋白表达水平下降。miR-26b联合1mmol/L顺铂在Mcl-1表达载体转染后对Hela细胞的杀伤活性(细胞活力抑制率为19.6±6.7)显著低于未转染Mcl-1表达载体的miR-26b联合1mmol/L顺铂组(细胞活力抑制率为55.7±7.6)。结论:MiR-26b通过靶向于Mcl-1增强顺铂对宫颈癌细胞系Hela的杀伤活性。 |
| 英文摘要: |
| objective: To investigate the effect of miR-26b on cisplatin therapy in cervical cancer in vitro. Methods: we detected the miR-26b level in normal cervical cell line CRL-2614 and cervical cancer cell lines Hela、SiHa和C-33a, using RT-qPCR. MTT assay was performed to measure the growth inhibition of miR-26b plus cisplatin in Hela cells. Bioinformatics and western blot were performed to determine whether the expression of Mcl-1 is regulated by miR-26b. Construct Mcl-1 expression vector, and then detected the role of Mcl-1 vector toward miR-26b plus cisplatin–inducing cytotoxicity in Hela cells by MTT assay. Results: A down-regulation of miR-26b was found in cervical cancer cell lines Hela (0.21±0.04), SiHa (0.42±0.03) and C-33a (0.33±0.03) than normal cervical cell line CRL-2614 (1.00±0.05). The miR-26b plus 1mmol/L cisplatin group showed a higher growth inhibition (52.6±6.9) than 1mmol/L cisplation group (6.7±3.5) in Hela cells. The expression of Mcl-1 at protein level was down-regulated after miR-26b transfection. The growth inhibition of Hela cells treated with miR-26b plus cisplatin was significantly decreased after the transfection of Mcl-1 expression vector. Conclusion: miR-26b sensitizes cisplatin-induced cytotoxicity by targeting in Mcl-1 in cervical cancer. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
